darolutamide
10 products
22 abstracts
Abstract
Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.Org: Divisions of Medical Oncology and Urology, Bayer Consumer Care AG,
Abstract
Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).Org: Universitätsklinikum rechts der Isar, Technical University Munich, Carolina Urologic Research Center and Genesis Care/Atlantic Urology Clinics, Loos, France, Espoo, Finland, Institut Gustave Roussy, University of Paris Saclay,
Abstract
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.Org: Bayer Ltd, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain,
Abstract
ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.Org: Georges Pompidou European Hospital, Pôle santé Léonard de Vinci, Centre d’oncologie et radiothérapie, ROC37, Finisterian Center of Radiotherapy and Oncology,
Abstract
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).Org: Catalan Institute of Cancer (ICO), Celcuity, Inc., Département Interdisciplinaire D’organisation Du Parcours Patient (DIOPP),
Abstract
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.Org: Saint Louis VA Medical Center, University of Massachusetts Lowell, St. Louis Veterans Affairs Medical Center,
Abstract
Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.Org: Saroj Gupta Cancer Centre and Research Institute, Apollo Multispecialty Hospital,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.Org: Roanoke, University Hospital Freiburg,
Abstract
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).Org: British Columbia Cancer Agency (BCCA), Vancouver Cancer Centre, Vancouver, BC, Canada, Huntsman Cancer Institute, Salt Lake City, UT, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, Urologicum Duisburg, Duisburg, Germany, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Brest, France, Kagawa University, Kagawa, Japan, Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Analysis of the efficacy and tolerance or darolutamide in combination with chemotherapy and ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Spanish population in a daily clinic.Org: Hospital Guadalajara, Hospital General De Segovia, Hospital de Segovia, Hospital de Guadalajara,
Abstract
Real-world treatment landscape in advanced metastatic castration resistant prostate cancer.Org: Johnson & Johnson Consumer, Janssen Research and Development, Janssen Pharmaceuticals, Research & Development, Immutep, Saint-Aubin, France, Johnson and Johnson Innovative Medicine, Spring House, PA,
Abstract
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.Org: University of Virginia Comprehensive Cancer Center, New York Cancer and Blood Specialists, Comprehensive Cancer Centers of Nevada, Kangpu Biopharmaceuticals,
Abstract
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.Org: University Hospitals Seidman Cancer Center and Case Western Reserve University, University of California, San Diego Health, Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Chesapeake Urology, Sumitomo Pharma America,
Abstract
A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Memorial Sloan Kettering Cancer Center, Bayer Consumer Care AG, Bayer HealthCare Pharmaceuticals Inc.,
Abstract
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.Org: National Cancer Center Hospital East, Kashiwa, Japan, Kobe University Hospital, National Hospital Organization Kyushu Medical Center, Osaka International Cancer Institute, Osaka, Japan, Tohoku University Hospital,
Abstract
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).Org: Carolina Urologic Research Center, Northwestern University Feinberg School of Medicine, Brigham and Women’s Hospital, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Michigan,
Abstract
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.Org: Dana-Farber Cancer Institute, Carolina Urologic Research Center, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG, Bayer PLC,
Abstract
Darolutamide and time to pain progression by disease volume in ARASENS.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, IREC, Cliniques universitaires Saint Luc, UCLouvain,
Abstract
Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Cancer Center at Brown University,
Abstract
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium, Northwestern University, Feinberg School of Medicine, Chicago, IL, Bayer Healthcare Company Ltd., Beijing, China, Bayer Healthcare Co Ltd, Beijing, China,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.Org: Fred Hutchinson Cancer Research Center, University of Washington and Fred Hutchinson Cancer Research Centre, Associated Medical Professionals of NY, Toho University Sakura Medical Center, First Urology,
Product
darolutamide + docetaxelProduct
DarolutamideProduct
Non-steroidal anti-androgenProduct
Novel hormonal therapyProduct
darolutamide, docetaxel, ADT